Milk thistle versus a common supplement to protect the liver during TB treatment
This study tests whether milk thistle (silymarin) or N-acetylcysteine, a common antioxidant supplement, can help prevent liver damage that can be caused by tuberculosis (TB) medications. If you are starting TB treatment, this trial may help protect your liver from side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a new diagnosis of active or latent TB (in lungs or elsewhere in the body).
- You are about to start or have just started the standard 6-month TB drug regimen.
- You are not taking other medications that can harm the liver (such as valproate, methotrexate, sulfonamides, regular acetaminophen, or alcohol).
- You are not taking systemic corticosteroids or antioxidant supplements (like vitamins E or C).
- You are not pregnant, breastfeeding, HIV-positive, or have advanced liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether two natural supplements—silymarin (milk thistle) and n-acetylcysteine—can protect the liver from damage caused by tuberculosis medications. If you qualify, you will receive one of these supplements along with your TB treatment to see which one helps prevent liver problems.
This trial tests if taking N-acetylcysteine (NAC) alongside standard TB treatment can help prevent long-term lung problems after tuberculosis. It is for people with moderate to severe TB who already have some reduced lung function.
This study compares two natural supplements, vitamin E and milk thistle (silymarin), to see which is better at reducing liver fat and improving liver health in people who have fatty liver disease but do not have diabetes.
This trial tests whether adding omega-3 (fish oil) to standard TB treatment helps clear the infection faster and reduces inflammation. You may be eligible if you have confirmed lung TB and meet a few health criteria.
This trial studies whether atorvastatin (a cholesterol medicine) can reduce ongoing inflammation after you finish standard tuberculosis (TB) treatment. If it works, it may improve how your body recovers after TB, especially by lowering inflammation-related signals.
This study looks at how often isoniazid, a medicine used to treat tuberculosis, causes liver damage in everyday practice, and what factors might predict that risk. If you are taking or have taken isoniazid, this research may help doctors understand your risk and improve safety for other patients.
Hear when a new Protection From Liver Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.